

Mutations in the *AHI1* Gene, Encoding Joubertin, Cause Joubert Syndrome with Cortical Polymicrogyria

Tracy Dixon-Salazar,¹ Jennifer L. Silhavy,¹ Sarah E. Marsh,¹ Carrie M. Louie,¹ Lesley C. Scott,¹ Aithala Gururaj,² Lihadh Al-Gazali,² Asma A. Al-Tawari,³ Hulya Kayserili,⁴ László Sztriha,² and Joseph G. Gleeson¹

¹Laboratory for Neurogenetics, Department of Neurosciences, University of California–San Diego, La Jolla; ²Department of Pediatrics, Faculty of Medicine and Health Sciences, United Arab Emirates University, Al Ain; ³Neurology Department, Children’s Unit, Al Sabah Hospital, Safat Al-Shewaikh, Kuwait; and ⁴Division of Medical Genetics, Institute of Child Health, Prenatal Diagnosis Research Center, University of Istanbul, Istanbul

Joubert syndrome (JS) is an autosomal recessive disorder marked by agenesis of the cerebellar vermis, ataxia, hypotonia, oculomotor apraxia, neonatal breathing abnormalities, and mental retardation. Despite the fact that this condition was described >30 years ago, the molecular basis has remained poorly understood. Here, we identify two frameshift mutations and one missense mutation in the *AHI1* gene in three consanguineous families with JS, some with cortical polymicrogyria. *AHI1*, encoding the Joubertin protein, is an alternatively spliced signaling molecule that contains seven Trp-Asp (WD) repeats, an SH3 domain, and numerous SH3-binding sites. The gene is expressed strongly in embryonic hindbrain and forebrain, and our data suggest that *AHI1* is required for both cerebellar and cortical development in humans. The recently described mutations in *NPHP1*, encoding a protein containing an SH3 domain, in a subset of patients with JS plus nephronophthisis, suggest a shared pathway.

Introduction

The mammalian cerebellum consists of two hemispheres and a midline structure known as the “vermis,” which is responsible for coordination of midline movements. The most common disorder affecting the development of this structure is Joubert syndrome (JS [MIM 213300]), but the molecular determinants of this condition are poorly understood. A key radiographic hallmark of JS is the “molar tooth malformation” (MTM) seen on axial brain imaging, which is a result of a malformed cerebellar vermis, thick and elongated cerebellar peduncles, and a deep interpeduncular fossa (Maria et al. 1997). There is significant clinical heterogeneity in conditions displaying cerebellar vermis hypoplasia and the MTM. Some patients display the classic form of JS that includes the MTM, ataxia, hypotonia, oculomotor apraxia, neonatal breathing abnormalities, and mental retardation without extra-CNS involvement. Others also exhibit ocular colobomas, polydactyly, liver fibrosis, cystic dysplastic kidneys, retinal blindness, and/or nephronophthisis (NPHP [MIM 256100]). Distinct syndromes seen with JS and the MTM have been identified and differ by

their extra-CNS phenotype (Saraiva and Baraitser 1992; Chance et al. 1999; Satran et al. 1999; Valente et al. 2003). Altogether, there appears to be no less than eight of these distinct syndromes, and they are collectively referred to as “Joubert syndrome and related disorders” (JSRD) or “cerebello-oculo-renal syndromes” (CORS [MIM 608091]). It is interesting that one of these syndromes is marked by JS with the addition of cortical polymicrogyria (Gleeson et al. 2004), a brain abnormality characterized by excessive cortical folding, shallow sulci with walls that are fused in the deepest portions, and a simplified four-layered or unlayered cortical architecture (Barkovich et al. 1999; Ribacoba Montero et al. 2002).

There is genetic heterogeneity that mirrors this clinical heterogeneity seen in JS. Three causative loci have been mapped, including *JBTS1/CORS1* at 9q34.3 (Saar et al. 1999), *JBTS2/CORS2* at 11 centromere (Keeler et al. 2003; Valente et al. 2003), and *JBTS3/CORS3* at 6q23 (Lagier-Tourenne et al. 2004). The phenotypes of the families mapping to *JBTS1* and *JBTS3* were similar, displaying minimal extra-CNS involvement. One of six patients mapping to the *JBTS1* locus displayed retinal dystrophy, and none showed NPHP or renal cysts, although these were not specifically tested in all patients. Likewise, only two of the seven *JBTS3*-mapped patients displayed extra-CNS involvement—specifically, retinal dysplasia. On the other hand, families mapping to *JBTS2* displayed strong evidence of kidney involvement and additional eye involvement. Of 11 patients, 6 displayed

Received August 27, 2004; accepted for publication September 14, 2004; electronically published October 4, 2004.

Address for correspondence and reprints: Dr. Joseph G. Gleeson, University of California–San Diego, Leightag 332, 9500 Gilman Drive, La Jolla, CA 92093-0691. E-mail: jogleeson@ucsd.edu

© 2004 by The American Society of Human Genetics. All rights reserved. 0002-9297/2004/7506-0005\$15.00

renal cysts or NPHP, 2 displayed retinal dysplasia, and 4 displayed optic coloboma. Together, the data suggest that the *JBTS1* and *JBTS3* phenotypes usually do not involve retinal or renal abnormalities, whereas these are frequently seen in the *JBTS2* phenotype.

Highlighting these genetic and phenotypic differences is the recent finding of a mutation in *NPHP1*—a gene mutated in some patients with NPHP or Senior Løken syndrome (NPHP with retinal dystrophy)—in two siblings with Senior Løken syndrome plus a mild form of JS (Parisi et al. 2004). The *NPHP1* gene encodes for the nephrocystin protein, which contains an SH3 domain, and has been implicated in intracellular signaling and possibly ciliary function (Hildebrandt et al. 1997; Otto et al. 2003).

Here, we show evidence that mutations in *AHI1*, which encodes the Joubertin protein at the *JBTS3* locus, cause JS with polymicrogyria. Findings similar to these were published in a recent article (Ferland et al. 2004), in which mutations in *AHI1* were seen with pure JS with no retinopathy or supratentorial involvement. The present work provides independent verification of the involvement of *AHI1* in Joubert syndrome and suggests a broader *AHI1* phenotype that includes a role in cortical development as well as cerebellar development.

Methods

Genotyping

Homozygosity mapping was performed on 18 consanguineous families that were previously excluded from linkage to the *JBTS1* and *JBTS2* loci. Subjects were mapped at six different markers spanning the *JBTS3* locus, which was previously defined by the markers *D6S1620* and *D6S1699* (Lagier-Tourenne et al. 2004). This study was performed in accordance with a University of California Human Subjects Committee–approved protocol.

After informed consent was obtained from all family members, blood samples were drawn, and DNA was extracted, using standard procedures. Microsatellite markers were amplified by standard PCR with primers that corresponded to sequence from the Human Genome Browser. Heat-denatured PCR products were loaded onto a 6% polyacrylamide gel containing urea and were run by electrophoresis for 2.5 h at 40°C. Bands were visualized using a standard silver-staining protocol (Promega).

Mutation Screening

Primers were designed for all coding exons and for at least 50 bp of the intronic sequence that contained the 5' and 3' splice junctions, by use of the Primer3 program (table A1 [online only]). PCR products were purified using an exonuclease I and shrimp-alkaline-phosphatase pro-

tol and were sequenced using an ABI 3100 genetic analyzer. Sequences were analyzed using Sequencher 4.1 software. Genomic sequence for human *AHI1* was obtained from the Human Genome Browser (accession numbers AJ606362, AJ459825, and AK024085) and was used for primer design.

Northern-Blot Analysis

Mouse probe DNA fragments for exons 6–10 were designed as stated above, by use of sequence from the mouse genome query of the Human Genome Browser (accession numbers NM_026203, BB615071, and BG297436). Probes were then labeled with [α - 32 P]dCTP, by use of the Stratagene Prime-It RmT Labeling Kit. A Clontech Multiple Tissue Mouse Northern (MTN) blot was used to test for expression. Mouse tissues from postnatal day 0 (P0) were used to isolate total mRNA by Trizol and were similarly analyzed by northern analysis. Northern blots were hybridized with the labeled probe, by use of the Clontech MTN ExpressHyb protocol.

RT-PCR

Total RNA from whole brain, cerebellum, and cortex of mice was isolated using a standard Trizol procedure, at five different time points. First-strand cDNA was generated using Superscript II (Invitrogen) with RNase H⁻ reverse transcriptase and oligo dT. cDNA was amplified with primers for Joubertin exons 6–9 and for *G3PDH*, by a 50- μ L reaction with a final primer concentration of 300 nM. Band intensities were quantified using ImageQuant v.1.1 (Molecular Dynamics), and each band intensity for Joubertin was standardized relative to its *G3PDH* control.

Animal Subjects

All work was done in accordance with the University of California–San Diego Animal Subjects Program.

Results

Mutations in *AHI1* Are Seen in JS

Two families (10 and 115) showed linkage across the entire *JBTS3* interval, and one family (144) refined the candidate interval by showing homozygosity at a single marker (*D6S292*), which suggests a double recombination (fig. 1). Four genes within *JBTS3* were chosen for candidate analysis: *AHI1*, *MAP7*, *OLIG3*, and *KIAA1244*. Of these, only *AHI1* and *MAP7* were adjacent to *D6S292*. *AHI1* mutational analysis of all coding exons in genomic DNA showed two frameshift mutations in exon 8 (fsX270) and exon 10 (fsX408) and one missense mutation in exon 10 (V443D). On the ba-




Figure 1 Mutations in *AH11*, which encodes Joubertin, lead to cerebellar vermis aplasia, the MTM, and cortical polymicrogyria. **A**, Genotypes of the three consanguineous families displaying evidence of linkage to the *JBTS3* locus. Affected members of family MTI (molar-tooth on brain imaging) 010 and MTI 115 display homozygosity for markers across the entire region (*double red bar*), whereas the affected individual in family MTI 144 shows homozygosity for only a single marker (*D6S292*), which suggests a double recombination. Triangles with question marks (?) represent unknown sex and affection status. **B**, Magnetic resonance imaging analysis of each of the *JBTS3*-linked families corresponding to the pedigrees above. *Top row*, Axial images showing the MTI (*blackened arrows*), frontal polymicrogyria (*unblackened arrows*), and thin corpus callosum (*arrow with C*). *Bottom row*, Midline sagittal images showing horizontal superior cerebellar peduncle (*arrowheads*). The asterisk (*) represents mega cisterna magna. Additional scans showing polymicrogyria in patient 144-2 can be found in figure A1 (online only). **C**, Sequence chromatograms corresponding to the families above. Family MTI 010 displays a single-base insertion at position 787 in exon 8, family MTI 115 displays a T1328A point mutation in exon 10, and family MTI 144 displays a 2-base deletion at positions 1188–89, each of which leads to deleterious mutations in the Joubertin protein.




Figure 2 Exonic structure of *AHI1* and the Jouberin protein, including patient mutations. *A*, The gene encoded in ~215 kb of genomic DNA and that contains 31 exons, 2 of which are alternatively spliced, producing shorter isoforms. Patient mutations are indicated by arrows and occur in exon 8 and exon 10. *B*, The predicted full-length human Jouberin protein gives a 1,196-aa message with seven WD40 repeats and an SH3 domain.

sis of these results, we named the predicted protein “Jouberin.”

Jouberin, Encoded by the AHI1 Gene, Is a Predicted Signaling Molecule

The human Jouberin protein has three known isoforms and contains seven WD40 domains and one SH3 domain (fig. 2). Both human *AHI1* and mouse *Ahi1* have been described elsewhere (Jiang et al. 2002), and human *AHI1* has been further characterized as having an N-terminal coiled-coil domain (Ferland et al. 2004). Numerous additional domains have been predicted in this protein by use of ScanProsite analysis; among them are multiple SH3-binding sites.

Database analysis and literature review showed that the human *AHI1* gene contains 31 exons; two that are alternatively spliced (exon 24a and exon 27a), giving rise to the different isoforms. Alternative splicing occurs in both the 5' UTR and the 3' end of the Jouberin protein after the WD repeats. The consequences of the 5' UTR alternative splicing are not readily apparent; however, the 3' splicing yields two isoforms of the protein that lack either the SH3 domain or the far C-terminus of the protein. Exon 24a is used for a message that is ~3.5 kb in size. Exon 27a is used for a truncated isoform that produces a message mirroring the full-length ~4.7-kb message. An earlier publication (Jiang et al. 2002) reported two other alternatively spliced exons, both of which encode alternate ORFs. However, no evidence for these splice variants could be found in the public database by

querying the spliced ESTs or mRNAs. The function of the gene is currently unknown, but the presence of the SH3 domain suggests a role as a signaling molecule.

In the affected child of family 10, the frameshift mutation in exon 8 is caused by the presence of an extra cytosine (787insC) in the ORF and truncates the Jouberin protein at amino acid 270, which eliminates the WD repeats and SH3 domain (figs. 1 and 2). The parents and unaffected siblings carry this mutation. In the affected child of family 144, the frameshift mutation in exon 10 is caused by a 2-base deletion (188-89delTG) in the ORF, truncating the protein at amino acid 408 and also eliminating the WD repeats and SH3 domain. Both parents and the unaffected sibling in this family carry this mutation. In both affected individuals of family 115, the missense mutation in exon 10 changes a valine to aspartic acid (V443D), a mutation that is not seen in the unaffected family members. The valine is an evolutionarily conserved amino acid, seen in all species that contain a Jouberin orthologue for which sequence was available (fig. 3). The mutation also segregates with the phenotype in this family. None of these mutations were observed in 50 Middle Eastern controls.

Patients with Jouberin Mutations Display JS Plus Polymicrogyria

The clinical features of the patients with Jouberin mutations were examined in detail (table 1). They displayed the clinical hallmarks of JS, and all had the MTM (fig. 1). None of these patients showed evidence of renal in-

Species	Protein Sequence	Chromosome	Gene/Accession#
Human	YLLRGSD ESPKVILFF EILDFLSVDEIKNN	6	<i>AHI1</i>
Chimp	YLLRGSD ESPKVILFF EILDFLSVDEIKNN	5	ENSPTRT00000034412.1
Mouse	YLLREFE CPKVI LF FEILDF LSMDEIKNN	10	<i>Ahi1</i>
Rat	YLLREFD ECPKVI LF FEILDF LSMDEIKNN	1	<i>Ahi1</i>
Pufferfish	YFVEQSD HSPKVL LF FEILDF ISMEEAKAN	10	CAG13180

Figure 3 Conservation of amino acids surrounding the mutation (V443D) in family 115. The mutated valine (V) is highlighted, and the boxed area shows the sequence conservation among diverse species.

involvement, but two, from the same family, displayed evidence of retinal dysplasia. These data are consistent with previous findings that this locus is not associated with striking retinal or renal involvement, and they suggest a role for this gene in cerebellar development.

These patients appear to have a supratentorial phenotype, with two patients in one family showing clear evidence of polymicrogyria, a disorder of cerebral cortex development in which there are supernumary small gyri. There was also evidence in these families of corpus colosum abnormalities. Both affected members of family 115 display a thin corpus colosum and frontal polymicrogyria, the single affected member of family 144 displays a thin corpus colosum and likely frontal polymicrogyria, and the single affected member of family 10 displays enlarged lateral ventricles. These data suggest a further role for the gene in development of the cortex.

Jouberin Is Expressed in Mouse Brain during Development

To characterize the function of Jouberin, a northern blot containing total mRNA was probed at a series of embryonic time points with mouse exons 6–10 of *Ahi1*,

a region that is not known to be alternatively spliced. Expression was first evident at embryonic day 7 (E7) and was also present at E11, E15, and E17, with the most intense band occurring at E15 (fig. 4). Each time point showed a single band at ~4.7 kb, which represents the full-length variant of mouse *Ahi1*. Northern-blot analysis was also performed to determine regional distribution of expression for P0 mouse. The strongest levels of expression were seen in the hindbrain and forebrain, which showed two bands at ~4.7 and 3.5 kb, corresponding to the full-length isoform and the isoform lacking the SH3 domain, respectively (Jiang et al. 2002). These data suggest that Jouberin is expressed strongly during periods of both cortical and cerebellar development, consistent with the phenotypes seen in these patients.

On the basis of the cortical and cerebellar phenotypes in these families, expression was characterized in these two regions separately, by RT-PCR analysis across the developmental spectrum. Whole brain, cerebellum, and cortex were isolated from mouse E14 through adulthood at several stages and were tested for expression by use of primers that amplified exons 6–9 to identify signal

Table 1
Phenotypic Characteristics of Patients with *AHI1* Mutations

CHARACTERISTIC	FINDING IN AFFECTED INDIVIDUAL ^a			
	10-1	115-1	115-3	144-2
National origin	Palestinian	Kuwaiti	Kuwaiti	Turkish
Exon with mutation	8	10	10	10
Nucleotide changes	787insC	T1328A	T1328A	1188–89delTG
Alterations in coding sequence	fsX270 ^b	V443D	V443D	fsX408 ^b
MTM	+	+	+	+
Cerebellar vermis aplasia/hypoplasia	+	+	+	+
Breathing abnormalities	+	NA	NA	+
Ataxia/hypotonia	+	+	+	+
Mental retardation	+	+	+	+
Oculomotor apraxia	+	+	+	+
Retinal involvement	NA	Rod-cone dysfunction	Rod-cone dysfunction	NA
Supratentorial abnormalities	Enlarged lateral ventricle	Thin corpus colosum, frontal polymicrogyria	Thin corpus colosum, frontal polymicrogyria	Thin corpus colosum, possible frontal polymicrogyria
Coloboma	–	–	–	–
Kidney involvement	–	–	–	NA
Other	–	–	–	Atrial septal heart defect

^a NA = not available; + = positive for the characteristic; – = negative for the characteristic.

^b fs = frameshift.




Figure 4 Northern-blot analysis of *Abi1* (Jouberin) expression patterns in mice. *A*, Total mouse embryonic (E) 7–17 polyA mRNA was probed with a fragment of *Abi1* corresponding to exons 6–10. Expression was first evident at E7 and remained strong at E11, E15, and E17. There is a single band at ~4.7 kb (arrow) corresponding to the mouse *Abi1* gene from the Human Genome Browser. *B*, Total mRNA from mouse organs, aged P0, probed with the same *Abi1* fragment. Strongest expression was shown in the hindbrain and forebrain, with two bands visualized at 4.7 kb and 3.5 kb (arrows), corresponding to the two major splice variants (fig. 3). Total mRNA loading control is shown below.

from only spliced message. Expression of Jouberin was detected in whole brain at all time points analyzed (fig. 5). Expression in cerebellum appeared maximal at E18 and P5, whereas expression in cerebral cortex appeared maximal at E16 and E18. This expression corresponds to the periods of maximal development of these two brain regions, with cortical development preceding cerebellar development by several days in mice (Goffinet and Rakic 2000). Expression continued through adulthood, but at lower levels. These data suggest that Jouberin may exert its major effect during late embryonic development.

Discussion

We present evidence that homozygous mutations in the *AHI1* gene lead to JS with polymicrogyria. Mutations in *AHI1* were found in patients with classic features of JS, including the MTM and cerebellar vermis hypoplasia, which are the current diagnostic criteria for JS. The majority of these patients did not display evidence of retinal involvement, and none displayed renal involvement, which suggests minimal overlap with the *JBTS2/CORS2* phenotype. In addition, polymicrogyria was seen in two—and possibly three—of four patients, whereas enlarged cerebral lateral ventricles and hypoplasia of the corpus callosum were seen in the remaining patients. This sug-

gests that a cerebral cortical phenotype exists among patients with JS and with *AHI1* mutations.

We recently identified a subtype of JS with polymicrogyria that was found in 2 of ~100 patients with posterior fossa malformations. These patients did not display mental retardation beyond the range expected in JS, spasticity, microcephaly, or seizures, which would be typical findings in patients with polymicrogyria (Gleeson et al. 2004). In addition, none of the patients presented here, who do not overlap with those published elsewhere, reported these findings. However, there is other evidence of a cerebral cortical phenotype among patients with linkage to the *JBTS3* locus, since one patient studied by Lagier-Tourenne et al. (2004) displayed spasticity, microcephaly, and seizures. The data together suggest that mutations in *AHI1* can produce typical JS, JS plus retinal involvement, or JS plus polymicrogyria but that renal involvement is uncommon among these patients.

The *AHI1* gene (“Abelson helper integration-1”) was named because of frequent integration of helper provirus at this locus in Abelson murine leukemia virus-induced lymphoma (Jiang et al. 2002). Involvement in leukemogenesis has been suggested by the high frequency of *AHI1* mutations seen in certain virus-induced murine leukemias. Expression is high in most primitive hematopoietic cells, with specific patterns of downregulation in different




Figure 5 RT-PCR of *Abi1* (Jouberin) expression in mouse whole brain, cerebellum, and cortex, at different time points. Band-intensity quantification (standardized against *G3PDH* controls) revealed that Jouberin showed increasing and then decreasing expression as development progressed. Maximum expression occurred in the cerebellum at E18 and P0, and maximum expression occurred in the cortex at E16 and E18. Decreased but persistent expression in the adult was also evident. *G3PDH* controls are shown below. C = negative control.

lineages (Jiang et al. 2004), which suggests that down-regulation is an important conserved step in primitive normal hematopoietic cell differentiation. Although the expression data that suggest a role for *AH11* in hematopoiesis is compelling, none of the patients presented here showed evidence of hematopoietic abnormalities on routine laboratory evaluations. Whether the gene plays a critical or redundant role in hematopoiesis remains to be determined.

We found that *Abi1* expression begins around E7 and continues through adulthood. Northern-blot analysis indicated the presence of two bands—a 4.7-kb and a 3.5-kb isoform—that correspond to the known transcripts from other organs, including brain (Jiang et al. 2002), although only the longer isoform was identified by Ferland et al. (2004) by northern-blot analysis.

Jouberin homologues were identified in all mammalian species examined, with high conservation in the WD40 and SH3 domains but lower conservation in the N- and C-termini. Highly conserved is the stretch of amino acids surrounding the V443D that was found to be mutated in family 115. An identical V443D mutation

was also found by Ferland et al. (2004), who also identified two other premature stop codons among three families with autosomal recessive JS without a cerebral cortical phenotype (Ferland et al. 2004). Family 115 resides in Kuwait, whereas the family with the V443D mutation studied by Ferland et al. (2004) resides in Saudi Arabia, which, because of the relative proximity of these countries, suggests a possible founder effect. Analysis by ScanProsite indicates that this residue may be part of a phosphorylation site by protein kinase C (PKC) at the serine that is 4 aa in the N-terminal direction (Jiang et al. 2002). Typically, there are hydrophobic amino acids such as valine after the serine in PKC sites, and a mutation of this residue to an aspartic acid might block this predicted phosphoprotein event. Although this finding is speculative, it raises the possibility that Jouberin may be a phosphoprotein under the control of PKC-related kinases.

The most highly conserved regions of Jouberin are the SH3 domain and the WD40 repeats. These domains are found in many signaling molecules, where they function as adaptor domains for protein-protein interactions.

SH3 domains typically bind to PXXP motifs (known as “SH3-binding domains”) to modulate these interactions. Recently, we showed that mutations in *NPHP1* are found in a subset of patients with JS combined with NPHP (Parisi et al. 2004), and it is interesting that both of the encoded proteins of *NPHP1* and the Joubertin protein contain highly conserved SH3 domains. Additionally, Joubertin contains multiple PXXP domains, which suggests that it may function with—or directly bind to—the *NPHP1* protein.

The NPHP gene family now consists of four genes of diverse function, but it is becoming increasingly clear that the NPHP proteins play critical roles in the function of the cilia. The encoded proteins for *NPHP1* and *NPHP2* colocalize to the primary cilia in renal epithelial cells (Otto et al. 2003). Furthermore, loss-of-function experiments in zebrafish and mice suggest that these proteins have roles in the establishment of left-right axis determination in motile cilia (Mochizuki et al. 1998) and in the pathogenesis of cystic kidney disease in non-motile cilia (Otto et al. 2003). The NPHP data suggest a possible role in cilia development, maintenance, or transport, although the direct mechanism has yet to be identified. The function of Joubertin remains to be determined, but it will be interesting to test for its interaction with the NPHP genes and its involvement in cilia function.

Acknowledgments

The authors thank the families, for their participation, and Ms. Anne John, for technical assistance. We thank the Joubert Syndrome Foundation for their support of this research. This work was funded by grants from the March of Dimes and the National Institute of Neurological Disorders and Stroke.

Electronic-Database Information

Accession numbers and URLs for data presented herein are as follows:

Human Genome Browser, <http://www.genome.ucsc.edu/> (for human sequence [accession numbers AJ606362, AJ459825, and AK024085] and mouse sequence [accession numbers NM_026203, BB615071, and BG297436])

Online Mendelian Inheritance in Man (OMIM), <http://www.ncbi.nlm.nih.gov/Omim/> (for JS, NPHP, and CORS)

Primer3, http://frodo.wi.mit.edu/cgi-bin/primer3/primer3_www.cgi

ScanProsite, <http://www.expasy.org/cgi-bin/scanprosite>

References

Barkovich AJ, Hevner R, Guerrini R (1999) Syndromes of bilateral symmetrical polymicrogyria. *Am J Neuroradiol* 20: 1814–1821

Chance PF, Cavalier L, Satran D, Pellegrino JE, Koenig M, Dobyns WB (1999) Clinical nosologic and genetic aspects

of Joubert and related syndromes. *J Child Neurol* 14:660–666

Ferland RJ, Eyaid W, Collura RV, Tully LD, Hill RS, Al-Nouri D, Al-Rumayyan A, Topcu M, Gascon G, Bodell A, Shugart YY, Ruvolo M, Walsh CA (2004) Abnormal cerebellar development and axonal decussation due to mutations in *AHI1* in Joubert syndrome. *Nat Genet* 36:1008–1013

Gleeson JG, Keeler LC, Parisi MA, Marsh SE, Chance PF, Glass IA, Graham JM Jr, Maria BL, Barkovich AJ, Dobyns WB (2004) Molar tooth sign of the midbrain-hindbrain junction: occurrence in multiple distinct syndromes. *Am J Med Genet* 125A:125–134

Goffinet AM, Rakic P (eds) (2000) *Mouse brain development*. Springer, Berlin

Hildebrandt F, Otto E, Rensing C, Nothwang HG, Vollmer M, Adolphs J, Hanusch H, Brandis M (1997) A novel gene encoding an SH3 domain protein is mutated in nephronophthisis type 1. *Nat Genet* 17:149–153

Jiang X, Hanna Z, Kaouass M, Girard L, Jolicoeur P (2002) *Ahi-1*, a novel gene encoding a modular protein with WD40-repeat and SH3 domains, is targeted by the *Ahi-1* and *Mis-2* provirus integrations. *J Virol* 76:9046–9059

Jiang X, Zhao Y, Chan WY, Vercauteren S, Pang E, Kennedy S, Nicolini F, Eaves A, Eaves C (2004) Deregulated expression in Ph⁺ human leukemias of *AHI-1*, a gene activated by insertional mutagenesis in mouse models of leukemia. *Blood* 103:3897–3904

Keeler LC, Marsh SE, Leeflang EP, Woods CG, Sztrija L, Al-Gazali L, Gururaj A, Gleeson JG (2003) Linkage analysis in families with Joubert syndrome plus oculo-renal involvement identifies the *CORS2* locus on chromosome 11p12-q13.3. *Am J Hum Genet* 73:656–662

Lagier-Tourenne C, Boltshauser E, Breivik N, Gribaa M, Betard C, Barbot C, Koenig M (2004) Homozygosity mapping of a third Joubert syndrome locus to 6q23. *J Med Genet* 41:273–277

Maria BL, Hoang KB, Tusa RJ, Mancuso AA, Hamed LM, Quisling RG, Hove MT, Fennell EB, Booth-Jones M, Ringdahl DM, Yachnis AT, Creel G, Frerking B (1997) “Joubert syndrome” revisited: key ocular motor signs with magnetic resonance imaging correlation. *J Child Neurol* 12:423–430

Mochizuki T, Saijoh Y, Tsuchiya K, Shirayoshi Y, Takai S, Taya C, Yonekawa H, Yamada K, Nihei H, Nakatsuji N, Overbeek PA, Hamada H, Yokoyama T (1998) Cloning of *inv*, a gene that controls left/right asymmetry and kidney development. *Nature* 395:177–181

Otto EA, Schermer B, Obara T, O’Toole JF, Hiller KS, Mueller AM, Ruf RG, Hoefele J, Beekmann F, Landau D, Foreman JW, Goodship JA, Strachan T, Kispert A, Wolf MT, Gagnadoux MF, Nivet H, Antignac C, Walz G, Drummond IA, Benzing T, Hildebrandt F (2003) Mutations in *INVS* encoding inversin cause nephronophthisis type 2, linking renal cystic disease to the function of primary cilia and left-right axis determination. *Nat Genet* 34:413–420

Parisi MA, Bennett CL, Eckert ML, Dobyns WB, Gleeson JG, Shaw DWW, McDonald R, Eddy A, Chance PF, Glass IA (2004) The *NPHP1* gene deletion associated with juvenile nephronophthisis is present in a subset of individuals with Joubert syndrome. *Am J Hum Genet* 75:82–91

Ribacoba Montero R, Garcia Pravia C, Astudillo A, Salas Puig

- J (2002) Bilateral fronto-occipital polymicrogyria and epilepsy. *Seizure Suppl* 11:298–302
- Saar K, Al-Gazali L, Sztriha L, Rueschendorf F, Nur-E-Kamal M, Reis A, Bayoumi R (1999) Homozygosity mapping in families with Joubert syndrome identifies a locus on chromosome 9q34.3 and evidence for genetic heterogeneity. *Am J Hum Genet* 65:1666–1671
- Saraiva JM, Baraitser M (1992) Joubert syndrome: a review. *Am J Med Genet* 43:726–731
- Satran D, Pierpont ME, Dobyns WB (1999) Cerebello-oculorenal syndromes including Arima, Senior-Loken and COACH syndromes: more than just variants of Joubert syndrome. *Am J Med Genet* 86:459–469
- Valente EM, Salpietro DC, Brancati F, Bertini E, Galluccio T, Tortorella G, Briuglia S, Dallapiccola B (2003) Description, nomenclature, and mapping of a novel cerebello-renal syndrome with the molar tooth malformation. *Am J Hum Genet* 73:663–670